Norge - norsk - Statens legemiddelverk

grünenthal gmbh - rosuvastatinkalsium - tablett, filmdrasjert - 10 mg

Norge - norsk - Statens legemiddelverk

grünenthal gmbh - rosuvastatinkalsium - tablett, filmdrasjert - 5 mg

Norge - norsk - Statens legemiddelverk

grünenthal gmbh - rosuvastatinkalsium - tablett, filmdrasjert - 20 mg

Norge - norsk - Statens legemiddelverk

grünenthal gmbh - rosuvastatinkalsium - tablett, filmdrasjert - 40 mg

Norge - norsk - Statens legemiddelverk

teva pharma b.v. (4) - tenofovirdisoproksilfumarat - tablett, filmdrasjert - 245 mg

Den europeiske union - norsk - EMA (European Medicines Agency)

alnylam netherlands b.v. - patisiran sodium - amyloidose, familiær - andre nervesystemet narkotika - onpattro er angitt for behandling av arvelig transthyretin-mediert amyloidose (hattr amyloidose) hos voksne pasienter med stadium 1 eller nivå 2 polynevropati.

Den europeiske union - norsk - EMA (European Medicines Agency)

merck sharp & dohme b.v. - doravirine - hiv-infeksjoner - antivirale midler til systemisk bruk - pifeltro is indicated, in combination with other antiretroviral medicinal products, for the treatment of adults, and adolescents aged 12 years and older weighing at least 35 kg infected with hiv 1 without past or present evidence of resistance to the nnrti class.

Den europeiske union - norsk - EMA (European Medicines Agency)

univar solutions bv - trientine dihydrochloride - hepatolentikulær degenerasjon - andre alimentary tract and metabolism products, - cufence er angitt for behandling av wilsons sykdom hos pasienter som er intolerante til d-penicillamin terapi, i voksne og barn i alderen 5 år eller eldre.

Den europeiske union - norsk - EMA (European Medicines Agency)

recordati rare diseases - osilodrostat fosfat - cushing syndrome - kortikosteroider for systemisk bruk - isturisa er angitt for behandling av endogent cushings syndrom hos voksne.

Den europeiske union - norsk - EMA (European Medicines Agency)

roche registration gmbh  - entrectinib - cancer; carcinoma, non-small-cell lung - antineoplastiske midler - rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (ntrk) gene fusion,who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, andwho have not received a prior ntrk inhibitorwho have no satisfactory treatment options. rozlytrek as monotherapy is indicated for the treatment of adult patients with ros1 positive, advanced non small cell lung cancer (nsclc) not previously treated with ros1 inhibitors.